Organization · Venture Capital
Ligase BioPartners
Ligase BioPartners is a Netherlands-based life-sciences investor focused on translating early-stage cancer science into ventures that develop clinical solutions. They partner with researchers to improve patient outcomes and accessibility.
Overview
What Ligase BioPartners does
What Ligase BioPartners is
Ligase BioPartners is a Netherlands-based life-sciences investor focused on translating early-stage cancer science into ventures that develop clinical solutions. They partner with researchers to improve patient outcomes and accessibility.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 28, 2026
Official channels
Find Ligase BioPartners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Ligase BioPartners as a funder
Investment thesis
Ligase BioPartners prioritizes durable therapies, accessible therapies, and areas of profound unmet clinical need. The firm creates and invests in companies that advance science, promote healthcare sustainability, and reduce disease burden.
Focus narrative
Ligase BioPartners invests in innovative companies with a focus on durable therapies, accessible therapies, and addressing unmet clinical needs. The organization supports founding teams through hands-on company building, leveraging its close relationship with the Oncode Institute and its partner institutions.
Value beyond capital
Ligase BioPartners adds value to portfolio companies through rigorous scientific and translational assessment, supporting discoveries as they move from the lab toward clinical application and market entry. The organization provides hands-on company building and leverages its network within the Dutch oncology ecosystem.
Focus and fit
- Stages
- Pre-seed · Seed
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 3
Portfolio context
Notable portfolio companies include: Simmunext: Collaborators at Radboud University Medical Center published findings on T-cell quality in adoptive therapy. Cyclomics: Secured investment to accelerate commercialization of ultra-sensitive cancer diagnostics. Laigo Bio: Closed Series A financing to advance next-generation oncology therapeutics. Single Cell Discoveries: A platform supporting precision oncology discovery and development. Flindr Therapeutics: Translating academic biology into small-molecule oncology programs. Genase Therapeutics: Focused on precision oncology therapeutics.
Common questions
What to know about Ligase BioPartners
Upseed classifies Ligase BioPartners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 28, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.